Connect with us

What’s next for mRNA vaccines?

Moderna mRNA vaccines are already in the works to reduce the health risks of latent viruses like Epstein-Barr virus and cytomegalovirus and to tackle additional…



Robert Langer, ScD, is the David H. Koch Institute professor at MIT and a co-founder of Moderna, the pharmaceutical company behind a COVID-19 mRNA vaccine. In this Q&A, he tells us about the present and future of these versatile vaccines.

Q: The technology behind mRNA vaccines has been available for decades, but it was only with the pandemic that we first saw a publicly available mRNA vaccine. Why didn’t this happen sooner?

RL: While it is true that over the last thirty years hundreds of scientists have worked on developing mRNA vaccines and therapeutics, real breakthroughs in making an effective and commercially viable mRNA vaccine were greatly accelerated by the COVID-19 pandemic. It’s important to realize that Moderna and others like BioNtech and Curevac were in clinical trials for multiple different vaccines and therapeutics at the time the COVID-19 crisis started in late 2019/early 2020.

In fact, Moderna had eight vaccines (including a personalized cancer vaccine, a vaccine against Zika virus, and a dual vaccine against metapneumovirus and a type of parainfluenza) in human clinical trials at that point. Moderna recognized the incredible and unique opportunity to quickly meet the global demand for a COVID-19 vaccine by leveraging our mRNA tools and technologies. All the necessary pieces were in place, such as the correct mRNA chemistry and the development of nanoparticles to protect the messenger RNA (this actually had part of its origins in our MIT lab for which I received the Millennium Technology Prize in 2008). So the organization refocused efforts on bringing a COVID-19 mRNA vaccine to patients as quickly as possible without compromising public safety.

Moderna scientists identified the ideal protein candidate on the coronavirus SARS-CoV-2 virus (the spike protein), determined the mRNA sequence necessary to encode for this protein and, six months later, was given FDA clearance to proceed.

The many advantages of mRNA versus traditional vaccines prompted scientists to use mRNA vaccines to fight SARS-CoV-2. These advantages include the ability to quickly update the vaccine as new variants emerge, the ability to develop combination vaccines to fight several variants (and pathogens) simultaneously, and the ability to rapidly scale to serve a global population.

What’s more, Moderna’s mRNA platform generates antigens with superior biological fidelity and a greater success rate than traditional vaccines—all in record time. mRNA vaccines don’t require a giant manufacturing plant to produce them. All mRNA vaccines and therapeutics can be produced at the same location via the same process.

Q: What are some other diseases or disorders against which mRNA vaccines can provide protection?

RL: Moderna mRNA vaccines are already in the works to reduce the health risks of latent viruses like Epstein-Barr virus (EBV) and cytomegalovirus (CMV) and to tackle additional areas of unmet need, including an all-in-one mRNA vaccine to treat COVID-19, seasonal flu, and respiratory syncytial virus (RSV). Additionally, Moderna plans to develop mRNA vaccines to help patients beat Herpes simplex virus (HSV), MS, cancer, and HIV once and for all.

HSV, CMV, and EBV are large viruses that gain entry into cells via multiple proteins. Identifying which proteins to target remains a challenge, as does the development of adjuvants to fine-tune the body’s immune response. In the case of HIV, the situation is particularly complex.

Simply put, the immune system must be rigorously trained to produce a specific type of antibody (broadly neutralizing antibody or bnAbs), that has been found to be effective at fighting HIV. Further, a truly protective HIV vaccine will likely require a combination of antigens to stimulate the formation of multiple bnAbs classes.

“The many advantages of mRNA versus traditional vaccines prompted scientists to use mRNA vaccines to fight SARS-CoV-2 “ [Crocothery/Getty Images]
Indeed, mRNA vaccines can provide protection against practically any viral or bacterial infection. Unlike traditional vaccines, mRNA vaccines enable the patient’s own cells to “train” the immune system to recognize a pathogen by producing the invader proteins the immune system will need to attack.

Therefore, mRNA vaccines are limited only by the immune system’s own ability to fight the pathogen. Once an ideal protein candidate is identified, it is a relatively simple process to identify the mRNA needed to encode for those proteins.

Q: Can mRNA vaccines provide universal protection against a family of viruses, such as coronaviruses?

RL: Theoretically, yes. AI, machine learning, and robotic process automation (RPA) are technologies that can help us more rapidly catalog common familial viral elements, predict potential variations and mutations, and identify antigen-protein targets—all while eliminating human error.

Further, these technologies can accelerate the process of identifying the ideal, most productive mRNA sequence needed to generate those proteins. Over time, AI/machine learning refinements will continuously improve the range and effectiveness of this approach by providing ever-larger datasets to draw from.

Q: Do mRNA vaccines have the potential to combat antimicrobial/antibiotic resistance?

RL: Yes. Antimicrobial and antibiotic resistance arises as a natural evolutionary process, the result of genetic variation (“errors”) and mutation in the pathogen, giving rise to novel traits. Organisms that develop traits which make them drug-resistant naturally survive and thrive.

First, mRNA vaccines have the potential to help combat antimicrobial and antibiotic resistance by reducing our reliance on traditional antibiotics. Additionally, Moderna’s mRNA platform helps combat resistance by identifying the most desirable and persistent antigens for targeting, by improving the prediction of new strains, and by accelerating the production of vaccines to defeat those strains.

Finally, by training the immune system to look for specific surface proteins on the bacterium, an mRNA vaccine more effectively targets specific pathogens while avoiding the issue of damaging a patient’s “good” bacteria with increasingly toxic antibiotics. For instance, through the selection of a “coat protein” as the target-antigen, an mRNA vaccine against a drug-resistant strain of malaria has already yielded encouraging results.

Q: On the whole, mRNA vaccines are safer, more efficient, and easier to produce than “traditional” vaccines. However, like with all technologies, there is always room to improve its accessibility, affordability, efficacy, and safety. Cold storage requirements and side effects including possible allergic reactions are some of the issues impacting uptake of these vaccines. Are there any solutions to these (or any other) issues that researchers are currently working upon?

RL: Moderna is leveraging AI and machine learning technologies to identify ways to make mRNA vaccines safer and more durable (with simpler refrigeration requirements) by minimizing the length of mRNA strands. Moderna is implementing a multi-pronged approach to ease the substantial global disease burden by making mRNA vaccines more widely accessible, affordable, efficient, and safe.

Moderna’s mRNA Access program aims to accelerate the creation of new mRNA vaccines through collaboration with global partners. mRNA Access lets outside researchers leverage Moderna’s platform to develop mRNA vaccines against emerging and neglected infectious diseases around the world.

This strategy exponentially expands our brain trust, making the discovery of safer and more efficient vaccines an inevitable outcome. To help ensure the success of our mission to combat the top respiratory diseases worldwide, Moderna has entered into ten-year supply agreements with strategic countries.

Finally, Moderna is expanding its COVID-19 vaccine technology patent-free into 92 additional low- and middle-income countries as well as building an mRNA manufacturing facility in Kenya.

In addition, at MIT, we are working on ways of creating self-boosting vaccines that can be given in a single injection that does not require the patient to return for boosters. We are also developing ways to create more stable nanoparticles, as well as microneedle patches that could be shelf stable and shipped around the world.

Q: Recently, there has been discussion about developing vaccines that can be administered as a pill or a nasal spray. Is this method of delivery possible for mRNA vaccines?

RL: The possibilities for vaccine administration are endless so long as an appropriate, effective delivery mechanism can be found that protects the mRNA from the local environments (e.g., mucus, saliva, stomach acid [HCL]) yet facilitates the delivery of mRNA into the cell. While the gold standard for vaccine administration is through an intramuscular shot in the arm, intranasal COVID-19 vaccines have already been shown to elicit strong cellular immune response in humans.

Additionally, at MIT, Gio Traverso and myself recently developed a self-orienting mRNA “milli-injector” capsule that uses a polymer coating to deliver mRNA to the stomach via milli-needle injections in the gastric lining, thereby avoiding damaging acids. The experiments successfully produced proteins in gastric mucosa, as well as systemic uptake though, due to volume restrictions, their effectiveness may be limited to diseases of the gastrointestinal tract.

Where logic meets illusion
“Theoretically, AI, machine learning, and robotic process automation (RPA) are technologies that can help us more rapidly catalog common familial viral elements, predict potential variations and mutations, and identify antigen-protein targets—all while eliminating human error.” [Moyo Studio/Getty Images]
One major roadblock to a nasal mRNA vaccine is nasal clearing. Mucus and nasal cilia act as a protective barrier against pathogens, typically a good thing. Unfortunately, antigen absorption decreases as nasal clearance increases. Another drawback to a nasal mRNA vaccine is cost since a specialized delivery system is required. Unlike an intramuscular injection, an intranasally administered vaccine must survive several biological obstacles to reach the target site and provide long-term protection.

A nasal vaccine’s formulation and delivery method must be precisely tuned and would require amplification via immunostimulants. Despite this, several vaccine companies are experimenting with intranasal delivery by tweaking nasal mucosal toxicity, mucoadhesion, and pH. AstraZeneca and the Chalmers University of Technology have initiated mRNA-based nasal spray vaccine development against SARS-CoV-2, where nasal vaccines make the most sense since viral invasion happens via the nasal mucosa.

Advantages of a pill or nasal spray include reduced patient hesitancy and increased compliance. Specific advantages of an intranasal spray include ease of combining vaccines, simple vaccine swapping to accommodate variants, a combined mucosal and systemic immune response, protection at distant mucosal sites, and a faster onset of a strong immune response.

Q: What are some other ways that mRNA vaccine technology can improve human wellbeing that you believe hasn’t yet had enough attention or curiosity?

RL: An mRNA vaccine enables the patient to produce proteins, but these proteins don’t have to be used to stimulate the immune system to fight disease. mRNA vaccine technology can be used to replace missing proteins in patients suffering from inherited metabolic disorders (of which hundreds exist, such as phenylketonuria). These potentially debilitating diseases are caused by an enzyme deficiency; the body is unable to manufacture or break down certain proteins.

Phenylketonuria (PKU) results in low levels of the enzyme phenylalanine hydroxylase, a protein that breaks down phenylalanine. Without it, phenylalanine builds up in the body, often to toxic levels, even causing brain damage. Current treatment is simply the dietary reduction of foods that contain phenylalanine (which includes much more than you think: all meats, milk, eggs, cheese, nuts, soy, beans, and more). The dietary requirements are so severe as to require supplementing with a special drink to ensure the essential nutrients.

Similarly, an mRNA vaccine may be used to potentially help treat depression by enabling patients to boost their levels of serotonin or dopamine to elevate their mood or reduce anxiety. In short, an mRNA vaccine can be used to express any protein and possibly treat almost any disease.

Q: What advice would you give to budding researchers interested in studying and working on mRNA vaccines?

RL: I think it’s important to realize that there are few limits. Whether it’s mRNA vaccines or anything else, I always tell my students to dream big dreams, dreams that can change the world. But if you do that you may run into obstacles. When I first discovered a way to deliver macromolecules including nucleic acids from small particles, I was ridiculed by the scientific community. My first nine research grants were rejected and no engineering department in the world would hire me for a faculty position. But I didn’t give up and I always tell my students to never give up either.

GEN wishes to thank David Olajide, consultant at CURZONPR in London, for providing the raw material for this article.

The post What’s next for mRNA vaccines? appeared first on GEN - Genetic Engineering and Biotechnology News.

Read More

Continue Reading


Positioning Is Worrying And Nobody Seems To Care

Positioning Is Worrying And Nobody Seems To Care

By Jan-Patrick Barnert and Michael Msika, Bloomberg Markets Live reporters and strategists




Positioning Is Worrying And Nobody Seems To Care

By Jan-Patrick Barnert and Michael Msika, Bloomberg Markets Live reporters and strategists

The market was braced for Nvidia’s earnings and they lived up to expectations, while the Fed minutes were pretty much a non-event. But the big picture is worrying: positioning is stretched and most investors don’t seem to care.

Some profit taking on tech stocks before the most anticipated earnings release of the season was hardly surprising. But now that Nvidia is out of the way, with the stock gaining 9% in post market trading, the big question is what investors will do about their very stretched equity exposure: build more, hold or start to unwind soon?

So far, portfolio managers have been busy buying into a bull trend perceived to have no ending. The Stoxx 600 is closing in on a record high and overbought levels, while CFTC future net positioning in dollar terms on the S&P 500 reached an all-time high earlier this month.

“Even post Tuesday’s selloff, indications of short-term US equity positioning remain stretched with quant funds, levered upside, momentum and call skew all more than two-thirds of the way to the levels that preceded two of the four largest S&P fragility events since 1928: Feb. 2018’s ‘Vixplosion’ and March 2020’s Covid shock,” say Bank of America derivatives strategists including Vittoria Volta. “With the pressure to chase momentum and fickle liquidity, fragility risks are high, though not extreme.”

That said, the strategists don’t see a bubble forming for the Magnificent 7 as their volatility has been falling, unlike during bubble episodes when price swings became more pronounced in concert with rising prices. “The decoupling between upside and downside vol in these stocks is reminiscent of the 2000s tech bubble, but earnings better meeting price-expectations and the asymmetry in Mag7’s macro reaction function suggests that this trend may be more due to the pain trade still being higher,” they say.

Europe hasn’t been immune to the tech hype — on the contrary. Tech is among the best performing Stoxx 600 sectors this year after a 9.1% surge, while ASML and SAP alone are responsible for a third of the benchmark’s gains and nearly half of the returns in the Euro Stoxx 50. Meanwhile, according to the BofA European fund managers survey, tech is now the most popular industry group, along with insurance. Following a massive surge in exposure last month, a net 32% of BofA’s respondents said they overweight the sector.

At the same time, tech sector breadth as measured by the short-term indicator of stocks trading above their 50-day moving average has weakened further. The indicator failed to confirm a top in the market as it had done multiple times over the past 18 months and instead decoupled from the wider benchmark as performance has become increasingly concentrated within a handful of stocks. This is most notable in the Nasdaq, where Nvidia and Meta account for almost 70% of this year’s gains.

Overall, describing markets as calm sounds increasingly like an understatement — at least when using the favored VIX curve indicator, which has now fallen to the lowest level since 2017. Together with a collapsing skew reading for the wider market and especially for tech stocks, plus a put-call ratio below 0.8, all the signs suggest that just about nobody cares about downside risk at this point.

Nomura cross-asset strategist Charlie McElligott explains it thus: “The key to equities seemingly being able to keep shaking off nascent pullbacks? Well outside of the ongoing ‘AI euphoria’ theme and de-grossing of shorts, which continues powering spectacular rallies in the ‘worst of’ junk companies, it’s been all about the Pavlovian ‘Options Selling’ — flows which continue to suppress volatility.”

And while this low-volatility, high-momentum market environment that’s free of big moves has encouraged almost every systematic investor from vol control to trend followers toward near-maximum exposure, their impact is subdued for the moment. But their positioning could act as a combustive agent if things go wrong.

“Just like gamma exposure, systematic flows aren’t always about direction; sometimes, they can simply act as stabilizing forces in the market,” say Tier1Alpha strategists. “That said, these funds still pose a significant risk to the equities market this week, as even a small uptick in volatility could result in some significant selling.”

“Across sector groups, positioning in mega-cap growth and tech continues to rise and is into the top decile, with net call volume surging to pandemic boom levels this week while flows into tech funds also resumed their strong run,” according to Deutsche Bank strategists Parag Thatte and Bankim Chadha. They add that equity allocations by CTAs rose further last week to hit the 83rd percentile.

Tyler Durden Thu, 02/22/2024 - 11:55

Read More

Continue Reading


The US Leading Economic Index Takes One For The Team

It was probably inevitable, but it’s striking nonetheless. The once-reliable US Leading Economic Index (LEI) has been signaling a US recession for more…



It was probably inevitable, but it’s striking nonetheless. The once-reliable US Leading Economic Index (LEI) has been signaling a US recession for more than a year but the economy has continued to expand. It’s a teachable moment in recession nowcasting and forecasting, but not surprising. The main takeaway, again: every recession indicator fails, eventually.

Why? It’s the nature of recessions. Every downturn’s different, the byproduct of a unique set of factors at a given point in time. There are similarities, but not enough so that you can easily select a handful of indicators that worked the last time and assume they’ll remain forever relevant in signaling future contractions.

The lesson, which I’ve been preaching for years – and is the core principle for The US Business Cycle Risk Report – is that the closest mere mortals can come to a “reliable” recession nowcasting/forecasting methodology is to aggregate signals from multiple, complimentary models.

But even combining models doesn’t suffice, if you pick a few and assume you’re done. There’s always room for improvement, in part because the economy is continually evolving, which may render a seemingly robust modeling effort less than robust at some point.

Keeping an eye open for new ways to profile the business cycle, in other words, is a key part of the analytics. For example, as I discussed earlier this week, aggregating state coincident indexes from the bottom up offers a potentially new and useful tool for enhancing existing recession nowcasting/forecasting analytics.

Meanwhile, what happened to the LEI? Ed Yardeni at sums up the problem:

The Conference Board, which compiles the two indexes, backed off its recession forecast. A spokesperson for the group said: “While the declining LEI continues to signal headwinds to economic activity, for the first time in the past two years, six out of its 10 components were positive contributors over the past six-month period (ending in January 2024).” She added. “As a result, the leading index currently does not signal recession ahead. While no longer forecasting a recession in 2024, we do expect real GDP growth to slow to near zero percent over Q2 and Q3.”

Rather than admit that the LEI has been misleading, The Conference Board tweaked the rule of thumb, which had been that three consecutive declines in the LEI signaled a looming recession. Now it’s how many of its components are falling over a six month period. In our opinion, the LEI is due for a product recall. It needs to be fixed to give more weight to the services sector. Here is January’s LEI contributions chart:

To be fair, the economy in the post-pandemic period has surprised on multiple fronts. My efforts at trying to screen out the noise from the signal have been affected, too, albeit temporarily, in late-2022, when it appeared that the US was on the verge of slipping into an NBER-defined recession. But by the spring of 2023, the signs were accumulating that the recession warning, which never reached a tipping point, was fading. Notably, the cornerstone of The US Business Cycle Risk Report – the Composite Recession Probability (CRPI) Index, which aggregates several business-cycle benchmarks — had pulled back from a moderate but not decisive recession warning in early 2023. Here’s how CRPI stacked up in mid-April 2023:

For comparison, here’s CRPI’s reading at last week’s close (Feb. 16):

To clear, there’s never 100% certainly in real time about estimating recession risk. It’s always possible that some new twist has rendered even the best of methodologies null and void at times.

The good news is that there’s a productive path to reduce the risk of failure and it starts by carefully diversifying the indicators that inform your analysis. For those who ignore this rule, a trap awaits: Every business-cycle indicator fails eventually. Fortunately, there’s a solution via the observation that there’s strength in numbers. Although any one recession indicator will likely fail at times, it’s highly unlikely that every indicator will fail simultaneously.  

How is recession risk evolving? Monitor the outlook with a subscription to:
The US Business Cycle Risk Report

Read More

Continue Reading


The Year Of Cascading Crises

The Year Of Cascading Crises

Authored by James Rickards via,

I often write about different crises, but usually one at…



The Year Of Cascading Crises

Authored by James Rickards via,

I often write about different crises, but usually one at a time. Whether it’s a market crash, recession, bank failures, etc. I take them on an individual basis.

But what about a cascade of crises? What about a situation in which one crisis comes after another for a prolonged period? Each crisis might be manageable, but the sheer volume of crises and their cumulative effect might push society to the breaking point.

It may seem hyperbolic at first glance, but it’s not — it’s entirely plausible. Now, I’m not necessarily predicting that we’ll get a cascade of crises. But it’s possible, and you should be prepared just in case.

That’s because it looks like 2024 might be a year in which the crises do cascade. And the crises will not be natural disasters (although that could happen) but more like social and political disasters.

Here’s what might play out over the next 10 months and the reasons why:

Much of what is to come is in response to the likely victory of Donald Trump in the race for the presidency. One cannot overstate the sheer fear of Trump by the globalists, Davos crowd, progressives, climate alarmists, DEI gurus and just about anyone else who can’t stand Trump.

This fear often manifests itself in the form of Trump derangement syndrome (TDS), which is a genuine form of mental illness, not just a simple disagreement with Trump’s policies. And TDS is contagious.

I’m not saying this to defend Trump (he has many flaws); I’m just pointing out the degree to which his critics hate and fear him.

Confidence in the Rule of Law Is Gone

The key question is:

“What would the anti-Trumpers in government and the media do to stop Trump?”

The answer is:

“Whatever it takes.”

Trump is not just an opposing politician; he’s an existential threat to a 50-year-old globalist, anti-nationalist agenda. To keep him out of the White House, his political opponents have resorted to lawfare: the use of law to handicap a political opponent.

We see this in the New York civil case in which a judge has now ruled that Trump and his companies must pay a $355 million fine (in addition to what may amount to $100 million in interest payments) for a non-crime. Trump simply did not commit fraud under any plausible interpretation of the law. No one even claims to have been defrauded.

There’s also the defamation verdict awarding $83 million to a plaintiff that is out of all proportion to any actual damages, and the classified documents case in Florida.

We also see elite attacks in the Jan. 6 case in Washington, D.C., the notorious Stormy Daniels hush money case brought by the biased and incompetent N.Y. District Attorney Alvin Bragg, the mass RICO case brought by the unethical and compromised Fulton County, Georgia, district attorney, Fani Willis — and finally the efforts to kick Trump’s name off the ballot using Section 3 of the 14th Amendment by claiming Trump is an “insurrectionist.”

Dubious at Best

All of these cases are legally dubious at best. While I’m not a constitutional scholar, I am an attorney with decades of legal experience. And based on that experience, it’s clear that these cases are politically motivated. But in their zeal to get Trump, prosecutors and judges may have overreached.

The Washington, D.C., case may be dismissed because the U.S. special prosecutor was not properly appointed under Department of Justice rules. There are also presidential immunity issues pending before the Supreme Court.

Meanwhile, the Georgia case may also be dismissed because of unethical conduct and lack of disclosure by Fani Willis. Damages in the defamation case may be greatly reduced on appeal.

Likewise, the Stormy Daniels case is on thin legal ice. And the Supreme Court is likely to rule any day that the 14th Amendment insurrection clause does not apply to Trump’s actions.

Meanwhile, it’s difficult to see how the Florida classified documents case can result in a conviction after the kid gloves treatment given to Joe Biden in his classified documents case.

And Trump can appeal the New York civil ruling, although it’ll be more difficult than a standard appeal because under the statute, Trump would have to turn over the entire $450 million while the appeal is decided. Trump’s rich, but that’s a lot of money even for a guy like Trump to round up.

New York Gov. Kathy Hochul has assured nervous New York business owners that they have nothing to fear from this ruling, urging them to remain in New York. But that just proves that this case was about nothing more than taking down Trump.

The Damage Is Done

The fact that Trump may survive this legal onslaught (or issue a self-pardon upon election) does not alter the damage done.

Confidence in the rule of law has been badly eroded. The biased and unbalanced application of the law to Trump has increased the already extreme polarization that exists in the U.S. This polarization is the foundation for the other social dysfunctions to follow.

Here’s a summary of the social and infrastructure crises that may follow on the political crisis described above:

  • Energy shortages and blackouts due to Green New Scam policies and the simple physics of trying to maintain a baseline load in the power grid using intermittent sources such as windmills and solar
  • A new pandemic promoted to impose unnecessary lockdowns that act as cover for ballot-box stuffing, extensive ballot harvesting, drop-box abuse and other scams intended to rig the vote for Biden
  • A stock market meltdown as Congress tries to reduce out-of-control fiscal deficits and markets realize that excessive government spending was the only thing keeping the economy going in the first place
  • The rollout of central bank digital currencies (CBDCs) that will be used as a surveillance tool to identify those whom Biden calls “enemies of the people.” The targets will be Trump supporters and MAGA Republicans
  • Chinese hacking of critical infrastructure systems including air traffic control, banking and capital markets.
  • As these crises cascade, don’t be surprised if the White House imposes martial law and even takes steps to suspend the elections.

Blood in the Streets

One event which I find highly likely and a possible cover for some of these other events is blood in the streets of Chicago from Aug. 19–21, 2024. That’s the time and place of the Democratic National Convention to nominate their candidate for president.

The convention will likely come under attack from Antifa, the pro-Palestinians, climate activists and others. The new mayor of Chicago, Brandon Johnson, is even more radical than Lori Lightfoot. He will let the demonstrators do what they want and tell the police to stand down. The riots, looting, arson and violence will take on a life of their own.

A good example of this is found in Norman Mailer’s book Miami and the Siege of Chicago (1968), which covered the riots at the Democratic convention (also in Chicago) in 1968 at the height of the war in Vietnam.

The difference between then and now is that in 1968, Chicago Mayor Richard Daley let the police pound the protestors into submission. This time, Brandon Johnson will let the protestors tear up the city. In any case, events of this type can be a catalyst for extreme remedies coming from the White House that could then be used to manipulate election results.

I realize that may sound paranoid or conspiratorial. But you have to realize the lengths to which these political operators will go to stop Trump. Once you do, you’ll see it’s not nearly as far-fetched.

What Can You Do to Survive?

The events I’m talking about would likely result in market turmoil. That’s why it’s prudent to increase your cash allocation, decrease your stock allocation (especially tech stocks) and have gold bullion coins and at least one monster box (containing 500 one-ounce American Silver Eagles available from the U.S. Mint). Land and fine art are other valuable assets.

Basically, you want assets that are not vulnerable to bank failure and are not in digital form because of hacking and power grid failures. If you are in stocks, I would allocate funds to major oil companies, major defense contractors, mining companies and agriculture firms such as Cargill and ADM. Treasury notes are another good play because interest rates should plunge in any recession emerging from the chaos.

Again, I’m not making a hard prediction that these events will occur. I’m simply stating that there’s a genuine possibility that they may occur, and that you should be prepared.

And as they say, an ounce of prevention is worth a pound of cure.

Tyler Durden Wed, 02/21/2024 - 16:15

Read More

Continue Reading